SlideShare a Scribd company logo
Biochempeg https://www.biochempeg.com
Stem Cell Therapy First Successful
In Treatment of Type 1 Diabetes
2021 is the 100th anniversary of the discovery of insulin. In 1921, insulin was discovered
by Sir Frederick G Banting, Charles H Best and JJR Macleod at the University of Toronto.
It was first used in a human to treat diabetes in 11 January 1922. Before 1921, it was
exceptional for people with type 1 diabetes to live more than a year or two. It is one of the
greatest medical discoveries of the 20th century, and it remains the only effective way to
treat type 1 diabetes today.
The discovery of insulin has saved millions of diabetic patients, especially those with type
1 diabetes. For patients with type 1 diabetes, it can only be maintained by insulin therapy,
and there is no other way to solve the fundamental problem that causes the disease -
pancreatic islet cells cannot produce insulin by themselves. Type 1 diabetes must be
treated with insulin, so it is also called insulin-dependent diabetes.
On October 18, 2021, Vertex Pharmaceuticals Incorporated announced that a patient with
severe type 1 diabetes has achieved a "stable recovery" of islet cell function after
receiving fully differentiated pancreatic islet cell replacement therapy derived from its stem
cell called VX-880. These restored pancreatic islet cells can make patients to regulate
insulin and even produce insulin by themselves, reducing their daily insulin consumption
by 91% and significantly improving blood sugar control. This is the world's first successful
case of stem cell therapy for type 1 diabetes.
About the VX-880
VX-880 is a stem cell-derived pancreatic islet cell replacement therapy, which aims to
restore the body's ability to regulate glucose by providing patients with pancreatic islet
cells derived from donor stem cells to produce insulin to replace insulin injection therapy
Biochempeg https://www.biochempeg.com
and long-term care. The safety of this therapy is similar to that of typical
immunosuppressive therapy, and no serious side effects related to the treatment have
been reported. Although there is only one patient's successful case, this is still enough to
prove the feasibility of this therapy.
Encapsulated stem cell-derived islets could shield β cells from the immune system (source:
reference [4])
In recent years, stem cell technology has been widely used in the intervention and
treatment of diabetes. As a cutting-edge technology in the clinical treatment of diabetes,
stem cell technology has attracted widespread attention. Many hospitals have
accumulated a lot of experience in rich clinical applications. How do stem cells work in the
treatment of type 1 diabetes?
Biochempeg https://www.biochempeg.com
The mechanism of stem cell therapy in the
treatment of diabetes
Stem cell therapy is currently recognized as the ultimate hope for a radical cure for
diabetes. Mesenchymal stem cells can secrete a variety of immunoregulatory factors and
nutritional factors to restore and repair a variety of damaged tissues. Due to easy
separation and low immunogenicity, mesenchymal stem cells are currently the most
widely used stem cells in clinical practice.
1. Type 1 diabetes and stem cells
Type 1 diabetes is an autoimmune response mediated by T cells, which leads to a lack of
pancreatic islet cells. The reason why it is difficult to overcome is due to the polyclonal
characteristics of the autoimmune response of type 1 diabetes and the characteristics of
multiple immune regulation disorders. Therefore, how to effectively control autoimmunity
is a key problem to be solved urgently in the treatment of type 1 diabetes. The treatment
shows that stem cells have immunomodulatory effects. Using the immunomodulatory
Biochempeg https://www.biochempeg.com
effect of stem cells to correct the autoimmunity of type 1 diabetes has been clinically
applied and achieved remarkable results as a novel therapy.
2. Type 2 diabetes and stem cells
The occurrence of type 2 diabetes is closely related to the significant decrease in the
sensitivity of insulin receptors in peripheral tissues, which leads to a decrease in the
utilization of blood sugar by tissue cells, and ultimately manifests as a significant increase
in blood sugar levels that are common in clinical practice. Mesenchymal stem cells have
strong migration and differentiation ability and can secrete a variety of good cytokines.
These factors can stimulate mesenchymal stem cells to exert immunosuppressive
functions, and a large number of well-grown stem cells can promote the survival of
damaged cells in a short time. Treatment with mesenchymal stem cells takes advantage
of their supportive role in secreting multiple cytokines and their ability to differentiate into
vascular endothelial cells.
Disadvantages of traditional treatments for
diabetes
Diabetes is a group of metabolic diseases characterized by hyperglycemia.
Hyperglycemia is caused by defective insulin secretion or impaired biological effects, or
both. The prolonged presence of hyperglycemia in diabetes leads to chronic damage and
dysfunction of various tissues, especially the eyes, kidneys, heart, blood vessels, and
nerves. There are generally two traditional methods of diabetes treatment, both of which
have obvious disadvantages.
One is the drug therapy. Although oral medications and insulin injections can improve
symptoms, they cannot precisely regulate blood sugar, reverse insulin resistance and
β cell dysfunction, reduce tissue and organ damage, and fundamentally treat diabetes.
Biochempeg https://www.biochempeg.com
The other one is transplantation of pancreas and islets. This kind of treatment is
expensive and the donors are very limited. It requires long-term administration of immune
preparations. It has large side effects, low operability, and cannot be widely used.
Compared with traditional treatments for diabetes, stem cell therapy is to repair one's own
pancreatic islet function and improve the symptoms of diabetes. With the stem cell
treatment, about 65% of patients have gotten rid of their dependence on insulin or oral
medications. More than 90% of patients have reduced the application dose of insulin or
oral drugs, or changed the injection of insulin to oral drug therapy, which greatly controlled
or slowed down the occurrence and development of complications.
Advantages of stem cell therapy for diabetes
◆Stem cell therapy can make diabetic patients stop using insulin or reduce insulin
dosage.
◆The safety of stem cell therapy in the treatment of diabetes has been effectively tested.
◆Stem cell therapy can effectively control fasting blood glucose, postprandial blood
glucose and hemoglobin (HbA1c) and other biochemical indicators.
◆Stem cell therapy can effectively prevent diabetic complications, such as diabetic foot.
Conclusion
The treatments showed that insulin-producing cells can be obtained from stem cells. Stem
cells represent an infinite source of cells and solve the problem of lack of donors. Diabetes
is a metabolic disease caused by the disorder of autoimmune processes. Only by solving
the original causes and mechanisms can the problem be solved. With the development of
scientific research, stem cell treatment of diabetes will make greater breakthroughs.
Biochempeg https://www.biochempeg.com
Stem cell technology is widely used now. In addition to treating diabetes, it can also be
used in muscle tissue regeneration, certain eye diseases, heart diseases, etc. In the
future, stem cell technology can also be used to cultivate organs in vitro.
For people with type 1 diabetes, the disease can only be controlled with insulin treatment.
For people with type 2 diabetes, it can be maintained by taking medication and dietary
controls. Semaglutide is an anti-diabetic medication used for the treatment of type 2
diabetes and chronic weight management. As a reliable PEG supplier, Biopharma
PEG provides four kind of semaglutide intermediates to support your R&D research or
commercial business. They are Fmoc-NH-PEG2-CH2COOH(CAS
NO.166108-71-0), NH2-PEG2-CH2COOH(CAS
NO.134978-97-5), Boc-NH-PEG2-CH2COOH(CAS
NO.108466-89-3) and CH2COOH-PEG2-NH2.HCl(CAS NO.134979-01-4).
References:
[1] First time: Stem cells successfully treat diabetic patients to regenerate insulin
[2] Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With
VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
[3] Mesenchymal stem cells: a future experimental exploration for recession of diabetic nephropathy
[4] How stem cells could fix type 1 diabetes

More Related Content

What's hot

Type 1 diabetes powerpoint
Type 1 diabetes powerpointType 1 diabetes powerpoint
Type 1 diabetes powerpointhloiselle14
 
Diabetes
DiabetesDiabetes
Diabetes
Sachin kumar
 
Diabetes risks and complications 2010
Diabetes risks and complications 2010Diabetes risks and complications 2010
Diabetes risks and complications 2010
Tracy Ross
 
Type 1 Diabetes
Type 1 DiabetesType 1 Diabetes
Type 1 Diabetes
eborglund
 
Type 2 diabetes mellitus
Type 2 diabetes mellitusType 2 diabetes mellitus
Type 2 diabetes mellitus
ThyagiArchana
 
Kouaka diabetes ptt (2)
Kouaka diabetes ptt (2)Kouaka diabetes ptt (2)
Kouaka diabetes ptt (2)KKouaka
 
Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...
Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...
Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...
Champlain Regional Coordination Centre
 
Type 3 diabetes
Type 3 diabetesType 3 diabetes
Type 3 diabetes
Heart Missionary Nelly
 
Epidemiology of Diabetes Mellitus
Epidemiology of Diabetes MellitusEpidemiology of Diabetes Mellitus
Epidemiology of Diabetes MellitusAjay Raj
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
ANIRBAN GHOSH
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
Mohammad Amir
 
Classific diabetes
Classific diabetesClassific diabetes
Classific diabetesnindhateukii
 
DIABETES MELLITUS ppt
DIABETES MELLITUS pptDIABETES MELLITUS ppt
DIABETES MELLITUS pptfatmata sesay
 
Type 2 diabetes - A 2016 update by Zeena Nackerdien
Type 2 diabetes - A 2016 update by Zeena NackerdienType 2 diabetes - A 2016 update by Zeena Nackerdien
Type 2 diabetes - A 2016 update by Zeena Nackerdien
Zeena Nackerdien
 

What's hot (20)

Type 2 Diabetes and Genes
Type 2 Diabetes and GenesType 2 Diabetes and Genes
Type 2 Diabetes and Genes
 
Type 1 Diabetes
Type 1 Diabetes Type 1 Diabetes
Type 1 Diabetes
 
Type 1 diabetes powerpoint
Type 1 diabetes powerpointType 1 diabetes powerpoint
Type 1 diabetes powerpoint
 
Diabetes
DiabetesDiabetes
Diabetes
 
Diabetes risks and complications 2010
Diabetes risks and complications 2010Diabetes risks and complications 2010
Diabetes risks and complications 2010
 
Type 1 Diabetes
Type 1 DiabetesType 1 Diabetes
Type 1 Diabetes
 
Type 2 diabetes mellitus
Type 2 diabetes mellitusType 2 diabetes mellitus
Type 2 diabetes mellitus
 
Kouaka diabetes ptt (2)
Kouaka diabetes ptt (2)Kouaka diabetes ptt (2)
Kouaka diabetes ptt (2)
 
Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...
Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...
Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...
 
Type 3 diabetes
Type 3 diabetesType 3 diabetes
Type 3 diabetes
 
Epidemiology of Diabetes Mellitus
Epidemiology of Diabetes MellitusEpidemiology of Diabetes Mellitus
Epidemiology of Diabetes Mellitus
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Classific diabetes
Classific diabetesClassific diabetes
Classific diabetes
 
DIABETES MELLITUS ppt
DIABETES MELLITUS pptDIABETES MELLITUS ppt
DIABETES MELLITUS ppt
 
Diabetes ppt
Diabetes pptDiabetes ppt
Diabetes ppt
 
Type 2 diabetes - A 2016 update by Zeena Nackerdien
Type 2 diabetes - A 2016 update by Zeena NackerdienType 2 diabetes - A 2016 update by Zeena Nackerdien
Type 2 diabetes - A 2016 update by Zeena Nackerdien
 
epidemilogy of diabetes
epidemilogy of diabetesepidemilogy of diabetes
epidemilogy of diabetes
 
Dm 2
Dm 2Dm 2
Dm 2
 

Similar to Stem cell therapy first successful in treatment of type 1 diabetes

"Insulin Independence" Summit on Capitol Hill
"Insulin Independence" Summit on Capitol Hill"Insulin Independence" Summit on Capitol Hill
"Insulin Independence" Summit on Capitol Hill
David Edelman
 
INSULIKE Tablets: A Phenotypic Nutrition for Natural Sugar Balance
INSULIKE Tablets: A Phenotypic Nutrition for Natural Sugar Balance INSULIKE Tablets: A Phenotypic Nutrition for Natural Sugar Balance
INSULIKE Tablets: A Phenotypic Nutrition for Natural Sugar Balance
Associate Professor in VSB Coimbatore
 
diabetes mellitus.pptx
diabetes mellitus.pptxdiabetes mellitus.pptx
diabetes mellitus.pptx
DrAakankshaSharma1
 
lifestyle disorders:diabetes
lifestyle disorders:diabeteslifestyle disorders:diabetes
lifestyle disorders:diabetesLee-Ann Kara
 
New Trends in Diabetes and nursing care plan
New Trends in Diabetes and nursing care planNew Trends in Diabetes and nursing care plan
New Trends in Diabetes and nursing care plan
fahmyahmed789
 
Islet Sciences Company Highlights
Islet Sciences Company HighlightsIslet Sciences Company Highlights
Islet Sciences Company Highlights
IsletSciencesInc
 
Oral hypogycemic agents
Oral hypogycemic agentsOral hypogycemic agents
Stem Cell Treatment By Dr. Pravin Patel (Vadodara)
Stem Cell Treatment By Dr. Pravin Patel (Vadodara)Stem Cell Treatment By Dr. Pravin Patel (Vadodara)
Stem Cell Treatment By Dr. Pravin Patel (Vadodara)
DrPravinPatelNevada
 
Anti-Diabetic Activity of Some Medicinal Plants
Anti-Diabetic Activity of Some Medicinal Plants Anti-Diabetic Activity of Some Medicinal Plants
Anti-Diabetic Activity of Some Medicinal Plants
IIJSRJournal
 
Heal with Hope: The Future of Diabetes Care with Stem Cell | Dr David Greene ...
Heal with Hope: The Future of Diabetes Care with Stem Cell | Dr David Greene ...Heal with Hope: The Future of Diabetes Care with Stem Cell | Dr David Greene ...
Heal with Hope: The Future of Diabetes Care with Stem Cell | Dr David Greene ...
Dr. David Greene Arizona
 
Pnas2013
Pnas2013Pnas2013
Pnas2013
Uriel Barkai
 
diabetes.pdf
diabetes.pdfdiabetes.pdf
diabetes.pdf
RenasilayWoo
 
DIABETES Type I & II , Stem cell therapy , Dr. Sharda Jain
DIABETES  Type I & II , Stem cell therapy , Dr. Sharda Jain DIABETES  Type I & II , Stem cell therapy , Dr. Sharda Jain
DIABETES Type I & II , Stem cell therapy , Dr. Sharda Jain
Lifecare Centre
 
Medical Facts of STEM CELL THERAPY in DIABETES Type I & II , Dr. Sharda Jain
Medical Facts of STEM CELL THERAPY in DIABETES  Type I & II , Dr. Sharda Jain Medical Facts of STEM CELL THERAPY in DIABETES  Type I & II , Dr. Sharda Jain
Medical Facts of STEM CELL THERAPY in DIABETES Type I & II , Dr. Sharda Jain
StemcellGP21
 
Future Of Nanomedicine In Diabetes Treatment.pdf
Future Of Nanomedicine In Diabetes Treatment.pdfFuture Of Nanomedicine In Diabetes Treatment.pdf
Future Of Nanomedicine In Diabetes Treatment.pdf
Pharmacy 7065
 
Newer Anti-Hyperglycemic agents in type 2 Diabetes Mellitus e Expanding the h...
Newer Anti-Hyperglycemic agents in type 2 Diabetes Mellitus e Expanding the h...Newer Anti-Hyperglycemic agents in type 2 Diabetes Mellitus e Expanding the h...
Newer Anti-Hyperglycemic agents in type 2 Diabetes Mellitus e Expanding the h...
Apollo Hospitals
 
Plegable
Plegable Plegable
Imeglmin Slides agents in Types 2 Diabetes Mellitus
Imeglmin Slides agents in Types 2 Diabetes MellitusImeglmin Slides agents in Types 2 Diabetes Mellitus
Imeglmin Slides agents in Types 2 Diabetes Mellitus
ameetrathod4
 
Diabetes
DiabetesDiabetes
Restoring Hope: Innovative Stem Cell Therapies for Diabetes | R3 Stem Cell
Restoring Hope: Innovative Stem Cell Therapies for Diabetes | R3 Stem CellRestoring Hope: Innovative Stem Cell Therapies for Diabetes | R3 Stem Cell
Restoring Hope: Innovative Stem Cell Therapies for Diabetes | R3 Stem Cell
R3 Stem Cell
 

Similar to Stem cell therapy first successful in treatment of type 1 diabetes (20)

"Insulin Independence" Summit on Capitol Hill
"Insulin Independence" Summit on Capitol Hill"Insulin Independence" Summit on Capitol Hill
"Insulin Independence" Summit on Capitol Hill
 
INSULIKE Tablets: A Phenotypic Nutrition for Natural Sugar Balance
INSULIKE Tablets: A Phenotypic Nutrition for Natural Sugar Balance INSULIKE Tablets: A Phenotypic Nutrition for Natural Sugar Balance
INSULIKE Tablets: A Phenotypic Nutrition for Natural Sugar Balance
 
diabetes mellitus.pptx
diabetes mellitus.pptxdiabetes mellitus.pptx
diabetes mellitus.pptx
 
lifestyle disorders:diabetes
lifestyle disorders:diabeteslifestyle disorders:diabetes
lifestyle disorders:diabetes
 
New Trends in Diabetes and nursing care plan
New Trends in Diabetes and nursing care planNew Trends in Diabetes and nursing care plan
New Trends in Diabetes and nursing care plan
 
Islet Sciences Company Highlights
Islet Sciences Company HighlightsIslet Sciences Company Highlights
Islet Sciences Company Highlights
 
Oral hypogycemic agents
Oral hypogycemic agentsOral hypogycemic agents
Oral hypogycemic agents
 
Stem Cell Treatment By Dr. Pravin Patel (Vadodara)
Stem Cell Treatment By Dr. Pravin Patel (Vadodara)Stem Cell Treatment By Dr. Pravin Patel (Vadodara)
Stem Cell Treatment By Dr. Pravin Patel (Vadodara)
 
Anti-Diabetic Activity of Some Medicinal Plants
Anti-Diabetic Activity of Some Medicinal Plants Anti-Diabetic Activity of Some Medicinal Plants
Anti-Diabetic Activity of Some Medicinal Plants
 
Heal with Hope: The Future of Diabetes Care with Stem Cell | Dr David Greene ...
Heal with Hope: The Future of Diabetes Care with Stem Cell | Dr David Greene ...Heal with Hope: The Future of Diabetes Care with Stem Cell | Dr David Greene ...
Heal with Hope: The Future of Diabetes Care with Stem Cell | Dr David Greene ...
 
Pnas2013
Pnas2013Pnas2013
Pnas2013
 
diabetes.pdf
diabetes.pdfdiabetes.pdf
diabetes.pdf
 
DIABETES Type I & II , Stem cell therapy , Dr. Sharda Jain
DIABETES  Type I & II , Stem cell therapy , Dr. Sharda Jain DIABETES  Type I & II , Stem cell therapy , Dr. Sharda Jain
DIABETES Type I & II , Stem cell therapy , Dr. Sharda Jain
 
Medical Facts of STEM CELL THERAPY in DIABETES Type I & II , Dr. Sharda Jain
Medical Facts of STEM CELL THERAPY in DIABETES  Type I & II , Dr. Sharda Jain Medical Facts of STEM CELL THERAPY in DIABETES  Type I & II , Dr. Sharda Jain
Medical Facts of STEM CELL THERAPY in DIABETES Type I & II , Dr. Sharda Jain
 
Future Of Nanomedicine In Diabetes Treatment.pdf
Future Of Nanomedicine In Diabetes Treatment.pdfFuture Of Nanomedicine In Diabetes Treatment.pdf
Future Of Nanomedicine In Diabetes Treatment.pdf
 
Newer Anti-Hyperglycemic agents in type 2 Diabetes Mellitus e Expanding the h...
Newer Anti-Hyperglycemic agents in type 2 Diabetes Mellitus e Expanding the h...Newer Anti-Hyperglycemic agents in type 2 Diabetes Mellitus e Expanding the h...
Newer Anti-Hyperglycemic agents in type 2 Diabetes Mellitus e Expanding the h...
 
Plegable
Plegable Plegable
Plegable
 
Imeglmin Slides agents in Types 2 Diabetes Mellitus
Imeglmin Slides agents in Types 2 Diabetes MellitusImeglmin Slides agents in Types 2 Diabetes Mellitus
Imeglmin Slides agents in Types 2 Diabetes Mellitus
 
Diabetes
DiabetesDiabetes
Diabetes
 
Restoring Hope: Innovative Stem Cell Therapies for Diabetes | R3 Stem Cell
Restoring Hope: Innovative Stem Cell Therapies for Diabetes | R3 Stem CellRestoring Hope: Innovative Stem Cell Therapies for Diabetes | R3 Stem Cell
Restoring Hope: Innovative Stem Cell Therapies for Diabetes | R3 Stem Cell
 

More from DoriaFang

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdf
DoriaFang
 
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfAntibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
DoriaFang
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
DoriaFang
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
DoriaFang
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
DoriaFang
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
DoriaFang
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
DoriaFang
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
DoriaFang
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
DoriaFang
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
DoriaFang
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdf
DoriaFang
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DoriaFang
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
DoriaFang
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
DoriaFang
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
DoriaFang
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
DoriaFang
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
DoriaFang
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
DoriaFang
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
DoriaFang
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
DoriaFang
 

More from DoriaFang (20)

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdf
 
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfAntibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdf
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
 

Recently uploaded

Recruiting in the Digital Age: A Social Media Masterclass
Recruiting in the Digital Age: A Social Media MasterclassRecruiting in the Digital Age: A Social Media Masterclass
Recruiting in the Digital Age: A Social Media Masterclass
LuanWise
 
amptalk_RecruitingDeck_english_2024.06.05
amptalk_RecruitingDeck_english_2024.06.05amptalk_RecruitingDeck_english_2024.06.05
amptalk_RecruitingDeck_english_2024.06.05
marketing317746
 
Premium MEAN Stack Development Solutions for Modern Businesses
Premium MEAN Stack Development Solutions for Modern BusinessesPremium MEAN Stack Development Solutions for Modern Businesses
Premium MEAN Stack Development Solutions for Modern Businesses
SynapseIndia
 
Building Your Employer Brand with Social Media
Building Your Employer Brand with Social MediaBuilding Your Employer Brand with Social Media
Building Your Employer Brand with Social Media
LuanWise
 
Maksym Vyshnivetskyi: PMO Quality Management (UA)
Maksym Vyshnivetskyi: PMO Quality Management (UA)Maksym Vyshnivetskyi: PMO Quality Management (UA)
Maksym Vyshnivetskyi: PMO Quality Management (UA)
Lviv Startup Club
 
Bài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.doc
Bài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.docBài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.doc
Bài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.doc
daothibichhang1
 
Project File Report BBA 6th semester.pdf
Project File Report BBA 6th semester.pdfProject File Report BBA 6th semester.pdf
Project File Report BBA 6th semester.pdf
RajPriye
 
Company Valuation webinar series - Tuesday, 4 June 2024
Company Valuation webinar series - Tuesday, 4 June 2024Company Valuation webinar series - Tuesday, 4 June 2024
Company Valuation webinar series - Tuesday, 4 June 2024
FelixPerez547899
 
Set off and carry forward of losses and assessment of individuals.pptx
Set off and carry forward of losses and assessment of individuals.pptxSet off and carry forward of losses and assessment of individuals.pptx
Set off and carry forward of losses and assessment of individuals.pptx
HARSHITHV26
 
VAT Registration Outlined In UAE: Benefits and Requirements
VAT Registration Outlined In UAE: Benefits and RequirementsVAT Registration Outlined In UAE: Benefits and Requirements
VAT Registration Outlined In UAE: Benefits and Requirements
uae taxgpt
 
ikea_woodgreen_petscharity_cat-alogue_digital.pdf
ikea_woodgreen_petscharity_cat-alogue_digital.pdfikea_woodgreen_petscharity_cat-alogue_digital.pdf
ikea_woodgreen_petscharity_cat-alogue_digital.pdf
agatadrynko
 
Authentically Social by Corey Perlman - EO Puerto Rico
Authentically Social by Corey Perlman - EO Puerto RicoAuthentically Social by Corey Perlman - EO Puerto Rico
Authentically Social by Corey Perlman - EO Puerto Rico
Corey Perlman, Social Media Speaker and Consultant
 
Business Valuation Principles for Entrepreneurs
Business Valuation Principles for EntrepreneursBusiness Valuation Principles for Entrepreneurs
Business Valuation Principles for Entrepreneurs
Ben Wann
 
FINAL PRESENTATION.pptx12143241324134134
FINAL PRESENTATION.pptx12143241324134134FINAL PRESENTATION.pptx12143241324134134
FINAL PRESENTATION.pptx12143241324134134
LR1709MUSIC
 
Affordable Stationery Printing Services in Jaipur | Navpack n Print
Affordable Stationery Printing Services in Jaipur | Navpack n PrintAffordable Stationery Printing Services in Jaipur | Navpack n Print
Affordable Stationery Printing Services in Jaipur | Navpack n Print
Navpack & Print
 
Putting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxPutting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptx
Cynthia Clay
 
3.0 Project 2_ Developing My Brand Identity Kit.pptx
3.0 Project 2_ Developing My Brand Identity Kit.pptx3.0 Project 2_ Developing My Brand Identity Kit.pptx
3.0 Project 2_ Developing My Brand Identity Kit.pptx
tanyjahb
 
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challenges
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challengesEvent Report - SAP Sapphire 2024 Orlando - lots of innovation and old challenges
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challenges
Holger Mueller
 
Sustainability: Balancing the Environment, Equity & Economy
Sustainability: Balancing the Environment, Equity & EconomySustainability: Balancing the Environment, Equity & Economy
Sustainability: Balancing the Environment, Equity & Economy
Operational Excellence Consulting
 
Bài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.doc.pdf
Bài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.doc.pdfBài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.doc.pdf
Bài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.doc.pdf
daothibichhang1
 

Recently uploaded (20)

Recruiting in the Digital Age: A Social Media Masterclass
Recruiting in the Digital Age: A Social Media MasterclassRecruiting in the Digital Age: A Social Media Masterclass
Recruiting in the Digital Age: A Social Media Masterclass
 
amptalk_RecruitingDeck_english_2024.06.05
amptalk_RecruitingDeck_english_2024.06.05amptalk_RecruitingDeck_english_2024.06.05
amptalk_RecruitingDeck_english_2024.06.05
 
Premium MEAN Stack Development Solutions for Modern Businesses
Premium MEAN Stack Development Solutions for Modern BusinessesPremium MEAN Stack Development Solutions for Modern Businesses
Premium MEAN Stack Development Solutions for Modern Businesses
 
Building Your Employer Brand with Social Media
Building Your Employer Brand with Social MediaBuilding Your Employer Brand with Social Media
Building Your Employer Brand with Social Media
 
Maksym Vyshnivetskyi: PMO Quality Management (UA)
Maksym Vyshnivetskyi: PMO Quality Management (UA)Maksym Vyshnivetskyi: PMO Quality Management (UA)
Maksym Vyshnivetskyi: PMO Quality Management (UA)
 
Bài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.doc
Bài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.docBài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.doc
Bài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.doc
 
Project File Report BBA 6th semester.pdf
Project File Report BBA 6th semester.pdfProject File Report BBA 6th semester.pdf
Project File Report BBA 6th semester.pdf
 
Company Valuation webinar series - Tuesday, 4 June 2024
Company Valuation webinar series - Tuesday, 4 June 2024Company Valuation webinar series - Tuesday, 4 June 2024
Company Valuation webinar series - Tuesday, 4 June 2024
 
Set off and carry forward of losses and assessment of individuals.pptx
Set off and carry forward of losses and assessment of individuals.pptxSet off and carry forward of losses and assessment of individuals.pptx
Set off and carry forward of losses and assessment of individuals.pptx
 
VAT Registration Outlined In UAE: Benefits and Requirements
VAT Registration Outlined In UAE: Benefits and RequirementsVAT Registration Outlined In UAE: Benefits and Requirements
VAT Registration Outlined In UAE: Benefits and Requirements
 
ikea_woodgreen_petscharity_cat-alogue_digital.pdf
ikea_woodgreen_petscharity_cat-alogue_digital.pdfikea_woodgreen_petscharity_cat-alogue_digital.pdf
ikea_woodgreen_petscharity_cat-alogue_digital.pdf
 
Authentically Social by Corey Perlman - EO Puerto Rico
Authentically Social by Corey Perlman - EO Puerto RicoAuthentically Social by Corey Perlman - EO Puerto Rico
Authentically Social by Corey Perlman - EO Puerto Rico
 
Business Valuation Principles for Entrepreneurs
Business Valuation Principles for EntrepreneursBusiness Valuation Principles for Entrepreneurs
Business Valuation Principles for Entrepreneurs
 
FINAL PRESENTATION.pptx12143241324134134
FINAL PRESENTATION.pptx12143241324134134FINAL PRESENTATION.pptx12143241324134134
FINAL PRESENTATION.pptx12143241324134134
 
Affordable Stationery Printing Services in Jaipur | Navpack n Print
Affordable Stationery Printing Services in Jaipur | Navpack n PrintAffordable Stationery Printing Services in Jaipur | Navpack n Print
Affordable Stationery Printing Services in Jaipur | Navpack n Print
 
Putting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxPutting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptx
 
3.0 Project 2_ Developing My Brand Identity Kit.pptx
3.0 Project 2_ Developing My Brand Identity Kit.pptx3.0 Project 2_ Developing My Brand Identity Kit.pptx
3.0 Project 2_ Developing My Brand Identity Kit.pptx
 
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challenges
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challengesEvent Report - SAP Sapphire 2024 Orlando - lots of innovation and old challenges
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challenges
 
Sustainability: Balancing the Environment, Equity & Economy
Sustainability: Balancing the Environment, Equity & EconomySustainability: Balancing the Environment, Equity & Economy
Sustainability: Balancing the Environment, Equity & Economy
 
Bài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.doc.pdf
Bài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.doc.pdfBài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.doc.pdf
Bài tập - Tiếng anh 11 Global Success UNIT 1 - Bản HS.doc.pdf
 

Stem cell therapy first successful in treatment of type 1 diabetes

  • 1. Biochempeg https://www.biochempeg.com Stem Cell Therapy First Successful In Treatment of Type 1 Diabetes 2021 is the 100th anniversary of the discovery of insulin. In 1921, insulin was discovered by Sir Frederick G Banting, Charles H Best and JJR Macleod at the University of Toronto. It was first used in a human to treat diabetes in 11 January 1922. Before 1921, it was exceptional for people with type 1 diabetes to live more than a year or two. It is one of the greatest medical discoveries of the 20th century, and it remains the only effective way to treat type 1 diabetes today. The discovery of insulin has saved millions of diabetic patients, especially those with type 1 diabetes. For patients with type 1 diabetes, it can only be maintained by insulin therapy, and there is no other way to solve the fundamental problem that causes the disease - pancreatic islet cells cannot produce insulin by themselves. Type 1 diabetes must be treated with insulin, so it is also called insulin-dependent diabetes. On October 18, 2021, Vertex Pharmaceuticals Incorporated announced that a patient with severe type 1 diabetes has achieved a "stable recovery" of islet cell function after receiving fully differentiated pancreatic islet cell replacement therapy derived from its stem cell called VX-880. These restored pancreatic islet cells can make patients to regulate insulin and even produce insulin by themselves, reducing their daily insulin consumption by 91% and significantly improving blood sugar control. This is the world's first successful case of stem cell therapy for type 1 diabetes. About the VX-880 VX-880 is a stem cell-derived pancreatic islet cell replacement therapy, which aims to restore the body's ability to regulate glucose by providing patients with pancreatic islet cells derived from donor stem cells to produce insulin to replace insulin injection therapy
  • 2. Biochempeg https://www.biochempeg.com and long-term care. The safety of this therapy is similar to that of typical immunosuppressive therapy, and no serious side effects related to the treatment have been reported. Although there is only one patient's successful case, this is still enough to prove the feasibility of this therapy. Encapsulated stem cell-derived islets could shield β cells from the immune system (source: reference [4]) In recent years, stem cell technology has been widely used in the intervention and treatment of diabetes. As a cutting-edge technology in the clinical treatment of diabetes, stem cell technology has attracted widespread attention. Many hospitals have accumulated a lot of experience in rich clinical applications. How do stem cells work in the treatment of type 1 diabetes?
  • 3. Biochempeg https://www.biochempeg.com The mechanism of stem cell therapy in the treatment of diabetes Stem cell therapy is currently recognized as the ultimate hope for a radical cure for diabetes. Mesenchymal stem cells can secrete a variety of immunoregulatory factors and nutritional factors to restore and repair a variety of damaged tissues. Due to easy separation and low immunogenicity, mesenchymal stem cells are currently the most widely used stem cells in clinical practice. 1. Type 1 diabetes and stem cells Type 1 diabetes is an autoimmune response mediated by T cells, which leads to a lack of pancreatic islet cells. The reason why it is difficult to overcome is due to the polyclonal characteristics of the autoimmune response of type 1 diabetes and the characteristics of multiple immune regulation disorders. Therefore, how to effectively control autoimmunity is a key problem to be solved urgently in the treatment of type 1 diabetes. The treatment shows that stem cells have immunomodulatory effects. Using the immunomodulatory
  • 4. Biochempeg https://www.biochempeg.com effect of stem cells to correct the autoimmunity of type 1 diabetes has been clinically applied and achieved remarkable results as a novel therapy. 2. Type 2 diabetes and stem cells The occurrence of type 2 diabetes is closely related to the significant decrease in the sensitivity of insulin receptors in peripheral tissues, which leads to a decrease in the utilization of blood sugar by tissue cells, and ultimately manifests as a significant increase in blood sugar levels that are common in clinical practice. Mesenchymal stem cells have strong migration and differentiation ability and can secrete a variety of good cytokines. These factors can stimulate mesenchymal stem cells to exert immunosuppressive functions, and a large number of well-grown stem cells can promote the survival of damaged cells in a short time. Treatment with mesenchymal stem cells takes advantage of their supportive role in secreting multiple cytokines and their ability to differentiate into vascular endothelial cells. Disadvantages of traditional treatments for diabetes Diabetes is a group of metabolic diseases characterized by hyperglycemia. Hyperglycemia is caused by defective insulin secretion or impaired biological effects, or both. The prolonged presence of hyperglycemia in diabetes leads to chronic damage and dysfunction of various tissues, especially the eyes, kidneys, heart, blood vessels, and nerves. There are generally two traditional methods of diabetes treatment, both of which have obvious disadvantages. One is the drug therapy. Although oral medications and insulin injections can improve symptoms, they cannot precisely regulate blood sugar, reverse insulin resistance and β cell dysfunction, reduce tissue and organ damage, and fundamentally treat diabetes.
  • 5. Biochempeg https://www.biochempeg.com The other one is transplantation of pancreas and islets. This kind of treatment is expensive and the donors are very limited. It requires long-term administration of immune preparations. It has large side effects, low operability, and cannot be widely used. Compared with traditional treatments for diabetes, stem cell therapy is to repair one's own pancreatic islet function and improve the symptoms of diabetes. With the stem cell treatment, about 65% of patients have gotten rid of their dependence on insulin or oral medications. More than 90% of patients have reduced the application dose of insulin or oral drugs, or changed the injection of insulin to oral drug therapy, which greatly controlled or slowed down the occurrence and development of complications. Advantages of stem cell therapy for diabetes ◆Stem cell therapy can make diabetic patients stop using insulin or reduce insulin dosage. ◆The safety of stem cell therapy in the treatment of diabetes has been effectively tested. ◆Stem cell therapy can effectively control fasting blood glucose, postprandial blood glucose and hemoglobin (HbA1c) and other biochemical indicators. ◆Stem cell therapy can effectively prevent diabetic complications, such as diabetic foot. Conclusion The treatments showed that insulin-producing cells can be obtained from stem cells. Stem cells represent an infinite source of cells and solve the problem of lack of donors. Diabetes is a metabolic disease caused by the disorder of autoimmune processes. Only by solving the original causes and mechanisms can the problem be solved. With the development of scientific research, stem cell treatment of diabetes will make greater breakthroughs.
  • 6. Biochempeg https://www.biochempeg.com Stem cell technology is widely used now. In addition to treating diabetes, it can also be used in muscle tissue regeneration, certain eye diseases, heart diseases, etc. In the future, stem cell technology can also be used to cultivate organs in vitro. For people with type 1 diabetes, the disease can only be controlled with insulin treatment. For people with type 2 diabetes, it can be maintained by taking medication and dietary controls. Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management. As a reliable PEG supplier, Biopharma PEG provides four kind of semaglutide intermediates to support your R&D research or commercial business. They are Fmoc-NH-PEG2-CH2COOH(CAS NO.166108-71-0), NH2-PEG2-CH2COOH(CAS NO.134978-97-5), Boc-NH-PEG2-CH2COOH(CAS NO.108466-89-3) and CH2COOH-PEG2-NH2.HCl(CAS NO.134979-01-4). References: [1] First time: Stem cells successfully treat diabetic patients to regenerate insulin [2] Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes [3] Mesenchymal stem cells: a future experimental exploration for recession of diabetic nephropathy [4] How stem cells could fix type 1 diabetes